GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (XTER:41O) » Definitions » Shiller PE Ratio

Outlook Therapeutics (XTER:41O) Shiller PE Ratio : (As of Sep. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Outlook Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Outlook Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Shiller PE Ratio Chart

Outlook Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Outlook Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Outlook Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Outlook Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outlook Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Shiller PE Ratio falls into.



Outlook Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Outlook Therapeutics's E10 for the quarter that ended in Jun. 2024 is calculated as:

For example, Outlook Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.827/132.5538*132.5538
=-0.827

Current CPI (Jun. 2024) = 132.5538.

Outlook Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201409 0.000 100.428 0.000
201412 -62.236 99.070 -83.271
201503 -148.353 99.621 -197.395
201506 -117.904 100.684 -155.225
201509 -173.311 100.392 -228.834
201512 -173.970 99.792 -231.084
201603 -28.813 100.470 -38.014
201606 -227.840 101.688 -296.997
201609 -34.214 101.861 -44.523
201612 -124.378 101.863 -161.853
201703 -56.848 102.862 -73.257
201706 -31.328 103.349 -40.181
201709 -40.272 104.136 -51.262
201712 -95.992 104.011 -122.334
201803 -43.145 105.290 -54.317
201806 -35.952 106.317 -44.824
201809 -24.017 106.507 -29.891
201812 -17.580 105.998 -21.984
201903 -17.346 107.251 -21.438
201906 -3.540 108.070 -4.342
201909 -6.511 108.329 -7.967
201912 -11.160 108.420 -13.644
202003 -6.516 108.902 -7.931
202006 -0.533 108.767 -0.650
202009 -1.325 109.815 -1.599
202012 -1.973 109.897 -2.380
202103 -1.512 111.754 -1.793
202106 -1.162 114.631 -1.344
202109 -1.360 115.734 -1.558
202112 -1.416 117.630 -1.596
202203 -1.634 121.301 -1.786
202206 -1.514 125.017 -1.605
202209 -1.212 125.227 -1.283
202212 -1.510 125.222 -1.598
202303 -0.486 127.348 -0.506
202306 -1.486 128.729 -1.530
202309 -1.003 129.860 -1.024
202312 -0.734 129.419 -0.752
202403 -7.369 131.776 -7.412
202406 -0.827 132.554 -0.827

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Outlook Therapeutics  (XTER:41O) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Outlook Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Outlook Therapeutics Business Description

Traded in Other Exchanges
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics Headlines

No Headlines